The 4,155-page full government funding measure released early on December 20th includes dozens of policy provisions that will have a significant impact on the life sciences industry and the FDA. While many of these provisions (collectively known as the Food and Drug Omnibus Reform Act, or FDORA) are familiar to AgencyIQ, most have been updated since their original introduction. In this explainer, we set out to analyze the FDA-related provisions of this mega-bill.
Fill out the form to read the full article.
